PMID- 17724008
OWN - NLM
STAT- MEDLINE
DCOM- 20071105
LR  - 20181201
IS  - 1109-3099 (Print)
IS  - 1109-3099 (Linking)
VI  - 6
IP  - 3
DP  - 2007 Jul-Sep
TI  - Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases.
PG  - 233-41
AB  - OBJECTIVE: Bisphosphonates are potent antiresorptive agents used for a spectrum 
      of metabolic bone diseases. The aim of this study was to compare the adverse 
      effects (AEs) of alendronate, etidronate and risedronate prescribed in a 
      non-selected population, attending a single institution on an outpatient basis. 
      DESIGN: 849 patients receiving either alendronate (n=710), etidronate (n=181) or 
      risedronate (n=130) were studied for a period of 1916 person-years. RESULTS: AEs 
      were reported by 25.2% [21% gastrointestinal (GI) system-related], 11.1% (9.9%) 
      and 20.8% (15.4%) of patients on alendronate/etidronate/risedronate, 
      respectively, resulting in permanent discontinuation in 21.0%, 7.7% and 13.8%, 
      respectively. The odds ratio (95% Ci) for AEs in the case of a history of gi 
      disease was 2.4 (1.4-3.8), 2.1 (0.8-5.1) and 2.5 (0.9-6.6), respectively. The 
      majority of AEs were of a mild nature and usually occurred within six months of 
      therapy initiation. The odds ratio for AEs given the concurrent use of NSAIDS was 
      2.0 (1.4-3.0), 0.8 (0.3-2.4) and 2.2 (0.8-5.9), respectively. CONCLUSIONS: 
      Etidronate appears to have a better Ae profile. Bisphosphonate AEs are fairly 
      mild, affect the gi system, occur most frequently in the presence of gi disease 
      or concurrent use of NSAIDS and tend to be of the same type in the event of 
      administration of a different bisphosphonate.
FAU - Anastasilakis, Athanasios D
AU  - Anastasilakis AD
AD  - Department of Endocrinology, Hippocration General Hospital, Thessaloniki, Greece. 
      anastath@endo.gr
FAU - Goulis, Dimitrios G
AU  - Goulis DG
FAU - Kita, Marina
AU  - Kita M
FAU - Avramidis, Avraam
AU  - Avramidis A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Hormones (Athens)
JT  - Hormones (Athens, Greece)
JID - 101142469
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
RN  - KM2Z91756Z (Risedronic Acid)
RN  - M2F465ROXU (Etidronic Acid)
RN  - X1J18R4W8P (Alendronate)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Alendronate/administration & dosage/adverse effects
MH  - Bone Density Conservation Agents/administration & dosage/*adverse effects
MH  - Diphosphonates/administration & dosage/*adverse effects
MH  - Etidronic Acid/administration & dosage/adverse effects/analogs & derivatives
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Middle Aged
MH  - Osteoporosis, Postmenopausal/*drug therapy
MH  - Risedronic Acid
MH  - Treatment Outcome
EDAT- 2007/08/29 09:00
MHDA- 2007/11/06 09:00
CRDT- 2007/08/29 09:00
PHST- 2007/08/29 09:00 [pubmed]
PHST- 2007/11/06 09:00 [medline]
PHST- 2007/08/29 09:00 [entrez]
PST - ppublish
SO  - Hormones (Athens). 2007 Jul-Sep;6(3):233-41.